4 days ago
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its PROMUS� Element� Everolimus-Eluting Coronary Stent System, the Company's third ...
video.tiscali.it    more  open  pop  

1 month ago
on long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden; paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction; ...
multimedia.boston.com    more  open  pop  

02:10 -4 days ago
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its PROMUS� Element� Everolimus-Eluting Coronary Stent System, the Company's third ...
break.com    more  open  pop  

02:09 -5 days ago
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its PROMUS® Element™ Everolimus-Eluting Coronary Stent System, the Company’s third ...
metacafe.com    more  open  pop  

7 months ago
Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the US Food and Drug Administration (FDA) to market its second-generation TAXUS� Libert� ...
pandora.tv    more  open  pop  

01:49 -1 year ago
Sept. 2005 - FDA has received a number of reports of adverse events that occurred in patients who received drug-eluting coronary stents and then stopped taking their ...
youtube.com    more  open  pop  

1 month ago
; a case report of a woman with bone pain; and Perspective articles on direct-to-consumer advertising of drug-eluting stents and on the tragedy of self-immolation in Afghanistan.
multimedia.boston.com    more  open  pop  

00:04 -2 years ago
Drug Eluting Stent Thrombosis www.askdrwiki.com
video.google.com    more  open  pop  

00:05 -2 years ago
askdrwiki.com
video.google.com    more  open  pop  

1 month ago
on long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden; paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction; ...
multimedia.boston.com    more  open  pop